Skip to main content

Digital PCR Market to Exhibit 17.2% CAGR and Reach USD 799.1 Million by 2026; Rise Remarkably on Account of Increasing Prevalence of Genetic Disorder Cases, reports Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Nov. 02, 2020 (GLOBE NEWSWIRE) — The global digital PCR market size is forecast to reach USD 799.1 million by 2026, attributed to the increasing prevalence of infectious diseases and genetic disorders worldwide. Digital PCR is the biotechnological advancement of conventional PCR and provides a reproducible and sensitive method of measuring the amount of RNA or DNA in a sample. According to this report, the market value was USD 224.9 million in 2018 and is likely to exhibit a CAGR of 17.2% within the forecast period of 2019 to 2026. As per geographical segmentation, North America earned the largest digital polymerase chain reaction market share with a revenue of USD 96.5 million earned in 2018. This is owing to the high prevalence and diagnosis rate of infectious disease and the availability of better healthcare facilities in the region.
Significant Industry Developments of the Digital PCR Market Include:January 2019 – A new series of digital PCR platform was launched by QIAGEN. This platform is based on the combined assay development expert technology of Qiagen and FORMULATRIX.October 2019 – dd-Check STEC Solution was launched by Bio-Rad Laboratories, Inc. for the detection of virulence genes from Shiga toxin-producing Escherichia coli (STEC).
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/digital-pcr-market-102014
Rise in Prevalence of Genetic Disorders to Aid in Expansion of MarketThe increasing prevalence of infectious and genetic diseases is a major digital polymerase chain reaction market growth driver. In addition to this, the advancement in medical technology and introduction of innovative devices for therapeutic purposes will also aid in expansion of the market in the coming years. These innovative devices include crystal dPCR, beam dPCR chip-based digital PCR, and droplet digital PCR.On the other side, high cost of digital polymerase chain reaction installation may pose a major challenge to the market growth. This, coupled with the lack of awareness about the availability of treatment options, especially in developing and under-developed nations, may hamper the overall market in the coming years.Nevertheless, the gradual shift towards chip-based dPCR from droplet dPCR by healthcare providers is expected to boost the market in the coming years.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/digital-pcr-market-102014
Increasing Prevalence of Genetic Disorders to help Asia Pacific Register Faster CAGR by 2026As per geographical segmentation, North America earned the largest digital polymerase chain reaction market share with a revenue of USD 96.5 million earned in 2018. This is owing to the high prevalence and diagnosis rate of infectious disease and the availability of better healthcare facilities in the region.In addition, there is high awareness among people about the availability of advanced dPCR devices as treatment options in the developed nations of the region. Furthermore, the increasing number of various cancer cases and metabolic diseases are also boosting the regional market.
Quick Buy –  Digital PCR Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102014
Bio-Rad, Sysmex Inostics, and Thermo Fisher to Hold Dominant Shares with Diverse PortfolioThe global digital PCR market is consolidated in nature owing to the presence of many players. Companies such as Thermo Fisher Scientific Inc., Sysmex Inostics, and Bio-Rad Laboratories, Inc., are holding majority shares in the market on account of their diverse portfolio of chip-based digital PCR and droplet digital PCR and continuous launch of innovative technologies by these companies at large.Other players operating in this market are emphasizing on mergers and acquisitions, contracts and agreements, or other collaborative methods to attract high digital PCR market revenue and attain a significant position in the market in the coming years.
List of Manufacturers in the Digital PCR Market include:QiagenJN MedsysMerck KGaAFluidign CorporationStilla TechnologiesThermo Fisher Scientific Inc.Sysmex InosticsBio-Rad Laboratories Inc.Other Players
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/digital-pcr-market-102014
Global Digital PCR Market Segmentation:By Type·               Droplet Digital PCR·               Chip-based Digital PCR·               OthersBy Product·               Instruments·               Reagents & ConsumablesBy Indication·               Infectious Diseases·               Oncology·               Genetic Disorders·               OthersBy End User·               Hospitals & Clinics·               Pharmaceutical & Biotechnology Industries·               Diagnostic Centers·               Academic & Research OrganizationBy Geography·               North America (the U.S. and Canada)·               Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)·               Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)·               Latin America (Brazil, Mexico, and the Rest of Latin America)·               Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/digital-pcr-market-102014
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline.
Have a Look at Related Reports:In-vitro Diagnostics (IVD) Market Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 – 2026Hepatitis C Drug Market Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026Schizophrenia Drugs Market Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026Point of Care (POC) Diagnostics Market Share and Global Trend By Product (Blood Glucose Monitoring, Infectious Diseases, Cardiometabolic Diseases, Pregnancy and Fertility Testing Products, Hematology Testing Products, Others), By End User (Hospitals Bedside, Physician’s Office Lab, Urgent Care & Retail Clinics, Home and Self Testing) and Geography Forecast till 2026Psoriatic Arthritis Treatment Market Share and Global Trend By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies) and Geography Forecast till 2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/digital-pcr-market-9708

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.